Pharma

Under the deal, MedRhythms would receive a $3 million upfront payment and could earn up to $117.5 million if certain milestones are met.

The round included a strategic investment from pharma giant Gilead Sciences to expand their partnership for decentralized and hybrid trials.

The company aims to help the self-testing market grow by licensing its core technology for transforming smartphones into IVD devices.

Also: Impiricus raises a $3 million seed, and health tech VC Flare Capital Partners closes its $350 million third fund.

It initially offers medicines and other healthcare products and services from over 500 independent sellers.

The company said it will use the financing to expand in Europe and the U.S., and develop new digital therapeutics with its pharma partners.

The multiyear agreement will focus on speeding clinical trials and drug development in oncology and nonalcoholic steatohepatitis.

The Series C comes about two years after another $150 million raise.

Also, MedLern announces a partnership to help train emergency nurses in India in trauma nursing.

The partnership with Zuellig Pharma includes Ensemble, Happify's therapeutic for treating major depressive disorder and generalized anxiety disorder, and a prescription digital therapeutic for chronic insomnia.